니코틴 껌 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, nicotine gum market size in 2026 is estimated at USD 1.6 billion, growing from 2025 value of USD 1.46 billion with 2031 projections showing USD 2.58 billion, growing at 9.93% CAGR over 2026-2031.

This report is Segmented by Dosage (Below 3 Mg and Above 3 Mg), by Flavor (Mint, Fruit, and Others), by End User (Male and Female), by Distribution Channel (Supermarkets/Hypermarkets, Drug Stores/Pharmacies, Online Retail Stores, and Other Distribution Channels), and by Geography (North America, Europe, Asia-Pacific, South America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Nicotine Gum Market Trends and Insights

Growing Awareness about the Harmful Effects of Smoking

The increasing awareness of smoking-related health risks drives the growth of the smoking cessation products and services market. Consumers' understanding of these risks, including lung cancer, heart disease, respiratory problems, and secondhand smoke effects, has increased the demand for evidence-based solutions over reliance on willpower alone. While smoking prevalence has decreased in many regions, population growth has led to a higher total number of smokers, maintaining the demand for cessation aids such as nicotine patches, gums, lozenges, and prescription medications. The medical community's recognition of nicotine dependence as a chronic condition, rather than a lifestyle choice, has validated the use of long-term nicotine replacement therapies (NRTs). This medical perspective has expanded the market beyond short-term solutions to include comprehensive, long-term addiction management approaches, incorporating behavioral support, counseling services, and digital health applications.

Global Anti-Smoking Initiatives and Public Health Campaigns

Government tobacco control initiatives drive nicotine gum demand through frameworks that combine taxation, regulation, and cessation support. The Australian government implemented new tobacco control regulations in April 2024 . These regulations aim to reduce the appeal and attractiveness of tobacco products by eliminating flavor additives and standardizing product packaging. The measures restrict tobacco companies' ability to target vulnerable populations through advertising. The regulations mandate standardized dimensions for tobacco packs, pouches, and cigarette sticks. The UK government allocated GBP 70 million annually to stop smoking services in 2024, aiming to help 360,000 people quit each year, expanding the nicotine replacement therapy market . The funding provides free nicotine replacement products, counseling services, digital support tools, and specialized programs for high-risk populations. The WHO Framework Convention on Tobacco Control supports market development through standardized approaches across jurisdictions, establishing guidelines for pricing, packaging, and cessation support programs . The framework promotes international cooperation, research sharing, and harmonized regulatory standards for tobacco control measures.

Intense Competition from Alternative Nicotine Replacement Therapies (NRTs)

The FDA's marketing authorization for twenty ZYN nicotine pouch products in January 2025 marks a significant shift in oral nicotine delivery options . Nicotine pouches eliminate the need for chewing, prevent jaw fatigue, and remain discreet under the lip, appealing to professionals who require subtlety in their workplace environments. Therapeutic vaping devices that replicate smoking behaviors receive increasing support from cessation clinics due to their effectiveness in mimicking traditional smoking habits. These new product categories divide consumer attention across multiple nicotine delivery formats, compelling nicotine gum manufacturers to highlight their established clinical background, proven safety record, and controlled dosage mechanisms to maintain their market position. The emergence of these alternative nicotine delivery systems creates additional competitive pressure in the traditional nicotine replacement therapy market.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Demand for Convenient and Discreet Smoking-Cessation Products
2. Innovations in Product Formulations and Flavored Gums
3. Limited Consumer Awareness

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The below 3 mg tier dominated in 2025, capturing 66.85% of the nicotine gum market share as light and moderate smokers selected gradual tapering programs. This dominance stems from user preference for lower systemic exposure and established pharmacy inventory patterns favoring 2 mg products. The segment provides stable revenue for existing manufacturers and serves as an initial option for new users attempting to quit. However, clinical prescribing patterns are evolving. Healthcare facilities now implement the Fagerstrom Test for Nicotine Dependence to personalize treatment and prevent under-dosing, which studies have identified as a common relapse factor.

The above 3 mg segment demonstrates the highest growth rate, with a projected 9.98% CAGR through 2031. Heavy smokers require the elevated initial plasma concentration to manage withdrawal symptoms during the crucial first 72 hours after quitting. Improved patient retention occuers in cessation programs when 4 mg gum is included in discharge packages, resulting in continued prescription refills after patients return home. Manufacturers have developed bi-layer high-dose formulations with enhanced texture to address previous user concerns about taste and throat discomfort. This shift toward higher doses increases the average selling price and enhances gross margins in the nicotine gum market.

Mint maintains market leadership with 44.97% of 2025 sales value, supported by its clean aftertaste and established presence in pharmacy channels. Mint-flavored nicotine gums dominate the market, driven by several factors that enhance their appeal and effectiveness. The refreshing and cooling sensation of mint not only masks the bitter taste of nicotine but also makes the gum more enjoyable for users. Leading manufacturers, responding to strong consumer demand, prioritize mint variants in their portfolios, ensuring robust brand recognition and widespread availability. With nicotine strengths of 2 mg, 4 mg, and 6 mg, mint-flavored gums cater to varying levels of nicotine dependence, offering tailored support for those looking to quit. Additionally, market trends highlight a surge in innovations, such as sugar-free and low-calorie mint options, amplifying their allure, particularly among health-conscious consumers.

The fruit category exhibits 9.99% CAGR through flavor diversification. Premium fruit-flavored variants demonstrate higher repurchase frequency and improved cessation success rates. Manufacturers respond by developing subtle warming profiles that target adult consumers within regulatory parameters. Advanced coated-core technology enables sustained flavor release, promoting complete consumption time and enhanced nicotine absorption, contributing to increased consumer retention in the nicotine gum market.

Complete Report Scope:

• By Dosage
  • Below 3 mg
  • Above 3 mg
• By Flavor
  • Mint
  • Fruit
  • Others
• By End User
  • Male
  • Female
• By Distribution Channel
  • Supermarkets/Hypermarkets
  • Drug Stores/Pharmacies
  • Online Retail Stores
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • United Kingdom
    • France
    • Sweden
    • Rest of Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Geography Analysis

North America accounted for 84.12% of revenue in 2025, driven by comprehensive insurance coverage, hospital-based opt-out protocols, and established retail networks. Indiana's "Quit Now" program reported 40% quit rates when combining nicotine replacement therapy with counseling, compared to 4-7% for unaided attempts in 2023. Canadian regulations require pharmacist involvement for specific products, providing professional oversight while maintaining accessibility. While FDA-cleared pouches and therapeutic vapes increase competition, nicotine gum maintains a strong user base who prefer its self-dosing capability and oral satisfaction.

The Asia-Pacific region demonstrates the highest growth rate at 10.44% CAGR through 2031. This growth stems from high smoking rates, particularly in lower-middle-income countries. South Asian markets offer significant potential, as research indicates major gaps in smoking cessation programs. These markets require improved coordination between anti-smoking organizations, policymakers, and healthcare professionals to develop more effective cessation strategies.

Europe maintains consistent demand through established healthcare systems. The United Kingdom provides annual funding for local smoking cessation services and the "Swap to Stop" program, which offers alternatives like nicotine gum to smokers. In Eastern Europe, lower purchasing power creates opportunities for smaller, more affordable packaging formats. South America, Africa, and the Middle East present growth potential as governments implement World Health Organization recommendations, though healthcare system development remains crucial. International companies partner with regional non-governmental organizations on smoking cessation initiatives to expand nicotine gum market presence.

1. Kenvue Inc.
2. Perrigo Company plc
3. Cipla Limited
4. Rusan Pharma Ltd
5. ITC Limited
6. Haleon plc
7. PL Developments
8. Tab Labs Ltd
9. Sunmark (McKesson)
10. Boots UK
11. Dr Reddy's Laboratories Ltd.
12. Fertin Pharma A/S
13. Enorama Pharma AB
14. Rogue Nicotine
15. Lucy Goods Inc.
16. CVS Health
17. Revolymer plc
18. Zydus Lifesciences Ltd.
19. Blip Products, Inc.
20. Nixit

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Awareness about the Harmful Effects of Smoking
  • 4.2.2 Global Anti-Smoking Initiatives and Public Health Campaigns
  • 4.2.3 Rising Demand for Convenient and Discreet Smoking Cessation Products
  • 4.2.4 Innovations in Product Formulations and Flavored Gums
  • 4.2.5 Physician Recommendations and Medical Support
  • 4.2.6 Collaborations with Healthcare Providers and Strategic Partnerships
• 4.3 Market Restraints
  • 4.3.1 Intense Competition from Alternative Nicotine Replacement Therapies (NRTs)
  • 4.3.2 Limited Consumer Awareness
  • 4.3.3 Side Effects and User Discomfort
  • 4.3.4 Public Perception Challenges
• 4.4 Consumer Behaviour Analysis
• 4.5 Regulatory Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Bargaining Power of Suppliers
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Degree of Competition

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Dosage
  • 5.1.1 Below 3 mg
  • 5.1.2 Above 3 mg
• 5.2 By Flavor
  • 5.2.1 Mint
  • 5.2.2 Fruit
  • 5.2.3 Others
• 5.3 By End User
  • 5.3.1 Male
  • 5.3.2 Female
• 5.4 By Distribution Channel
  • 5.4.1 Supermarkets/Hypermarkets
  • 5.4.2 Drug Stores/Pharmacies
  • 5.4.3 Online Retail Stores
  • 5.4.4 Other Distribution Channels
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Rest of North America
  • 5.5.2 Europe
    • 5.5.2.1 United Kingdom
    • 5.5.2.2 France
    • 5.5.2.3 Sweden
    • 5.5.2.4 Rest of Europe
  • 5.5.3 Asia-Pacific
  • 5.5.4 South America
  • 5.5.5 Middle East and Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (Includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Info, Market Rank/Share, Products and Services, Recent Developments)
  • 6.4.1 Kenvue Inc.
  • 6.4.2 Perrigo Company plc
  • 6.4.3 Cipla Limited
  • 6.4.4 Rusan Pharma Ltd
  • 6.4.5 ITC Limited
  • 6.4.6 Haleon plc
  • 6.4.7 PL Developments
  • 6.4.8 Tab Labs Ltd
  • 6.4.9 Sunmark (McKesson)
  • 6.4.10 Boots UK
  • 6.4.11 Dr Reddy's Laboratories Ltd.
  • 6.4.12 Fertin Pharma A/S
  • 6.4.13 Enorama Pharma AB
  • 6.4.14 Rogue Nicotine
  • 6.4.15 Lucy Goods Inc.
  • 6.4.16 CVS Health
  • 6.4.17 Revolymer plc
  • 6.4.18 Zydus Lifesciences Ltd.
  • 6.4.19 Blip Products, Inc.
  • 6.4.20 Nixit

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK